By targeting RCC1-dependent cancer survival mechanisms, combination therapies with RCC1 inhibitors and standard chemotherapeutics could provide robust treatment options, enhance therapeutic outcomes, and address chemoresistance challenges. This evidence concerns the gene RCC1 and cancer.